LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.22 -1.61

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.22

Max

1.22

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.7M -24M
EPS	-0.354
Angestellte	49
EBITDA	-5.3M -28M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+115.32% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	14. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-7.4M 74M
Vorheriger Eröffnungskurs	2.83
Vorheriger Schlusskurs	1.22

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Mai 2026, 23:55 UTC

Ergebnisse

Review & Preview: Still Going Strong -- Barrons.com

8. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Mai 2026, 20:49 UTC

Ergebnisse

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8. Mai 2026, 20:25 UTC

Ergebnisse

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8. Mai 2026, 19:43 UTC

Ergebnisse

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8. Mai 2026, 19:43 UTC

Ergebnisse

Cencosud 1Q Net $115M

8. Mai 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8. Mai 2026, 19:18 UTC

Ergebnisse

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8. Mai 2026, 19:16 UTC

Ergebnisse

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8. Mai 2026, 19:08 UTC

Ergebnisse

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8. Mai 2026, 19:05 UTC

Ergebnisse

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8. Mai 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8. Mai 2026, 18:51 UTC

Ergebnisse

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8. Mai 2026, 18:49 UTC

Ergebnisse

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8. Mai 2026, 18:41 UTC

Ergebnisse

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8. Mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8. Mai 2026, 17:14 UTC

Ergebnisse

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8. Mai 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8. Mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. Mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Mai 2026, 15:39 UTC

Market Talk

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8. Mai 2026, 15:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. Mai 2026, 15:39 UTC

Market Talk

Canada's Job Market Sees Worst Start in Years -- Market Talk

8. Mai 2026, 15:36 UTC

Market Talk

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8. Mai 2026, 15:20 UTC

Market Talk

'Altcoin Season' Indicator on the Rise -- Market Talk

8. Mai 2026, 15:20 UTC

Market Talk

Ergebnisse

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8. Mai 2026, 15:05 UTC

Market Talk

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8. Mai 2026, 14:42 UTC

Market Talk

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8. Mai 2026, 14:39 UTC

Market Talk

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

115.32% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 115.32%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.